A cross-practice team co-authored a Dec. 18 article published in Law360 that provides insights on the Right to Try Act pathway that provides patients not eligible for clinical trial enrollment with ways to obtain investigational drugs or biologics for therapeutic use, and the “expanded access” or compassionate use provision that also grants access to investigational drugs.
Health care partner Mark Barnes (Boston), life sciences partner Greg Levine (Washington, D.C.), health care associate David Peloquin (Boston) and corporate practice associate Michael DiMaio (Boston) examine recent changes made by the U.S. Food and Drug Administration to the expanded access program to provide investigational therapies. The authors also analyze RTT and EA provisions impacting biopharmaceutical manufacturers.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.